Randomised treatment effects on major clinical outcomes at 90 days, by non-China versus China
| Outcome | Randomised treatment, n (%) | OR (95% CI) | p Value for interaction | |
| Low-dose | Standard-dose | |||
| Death or disability: mRS scores 2–6 | ||||
| Non-China | 505/901 (56.0) | 494/896 (55.1) | 1.04 (0.86 to 1.25) | 0.45 |
| China | 350/706 (49.6) | 323/703 (45.9) | 1.16 (0.94 to 1.43) | |
| Death or major disability: mRS scores 3–6 | ||||
| Non-China | 351/901 (39.0) | 357/896 (39.8) | 0.96 (0.8 to 1.16) | 0.31 |
| China | 254/706 (36.0) | 235/703 (33.4) | 1.12 (0.9 to 1.39) | |
| Shift in scores on the mRS | ||||
| Non-China | 0.93 (0.79 to 1.09) | 0.15 | ||
| 0 (no symptoms at all) | 201/901(22.3) | 183/896(20.4) | ||
| 1 (no significant disability despite symptoms) | 195/901(21.6) | 219/896 (24.4) | ||
| 2 (slight disability) | 154/901 (17.1) | 137/896 (15.3) | ||
| 3 (moderate disability requiring some help) | 130/901 (14.4) | 121/896 (13.5) | ||
| 4 (moderate-severe disability requiring assistance with daily living) | 95/901 (10.5) | 72/896 (8.0) | ||
| 5 (severe disability, bed-bound and incontinent) | 50/901 (5.5) | 51/896 (5.7) | ||
| 6 (death) | 76/901 (8.4) | 113/896 (12.6) | ||
| China | 1.1 (0.92 to 1.33) | |||
| 0 (no symptoms at all) | 202/706 (28.6) | 214/703 (30.4) | ||
| 1 (no significant disability despite symptoms) | 154/706 (21.8) | 166/703 (23.6) | ||
| 2 (slight disability) | 96/706 (13.6) | 88/703 (12.5) | ||
| 3 (moderate disability requiring some help) | 81/706 (11.5) | 60/703 (8.5) | ||
| 4 (moderate-severe disability requiring assistance with daily living) | 70/706 (9.9) | 82/703 (11.7) | ||
| 5 (severe disability, bed-bound and incontinent) | 39/706 (5.5) | 36/703 (5.1) | ||
| 6 (death) | 64/706 (9.1) | 57/703 (8.1) | ||
| Death during follow-up at 90 days | ||||
| Non-China | 76/946 (8.0) | 113/932 (12.1) | 0.63 (0.47 to 0.86) | 0.02 |
| China | 64/708 (9.0) | 57/711 (8.0) | 1.14 (0.79 to 1.66) | |
AOR, adjusted OR; mRS, modified Rankin Scale.